Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | PER2 | O15055 | 5/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22348923 | 0.88 | DPP4 (0.47) | DPP4PIK3CDCYP3A4TSHRTDP1 | |
| SCHEMBL6545587 | 0.87 | PIK3CD (0.54) | DPP4PIK3CDCYP3A4TSHRTDP1 | |
| SCHEMBL14170266 | 0.78 | MMP1 (0.39) | PIK3CDMMP1MMP3 | |
| SCHEMBL1527371 | 0.78 | CYP3A4 (0.39) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL1527372 | 0.78 | CYP3A4 (0.39) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL4704959 | 0.78 | CYP3A4 (0.39) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL7804695 | 0.76 | L3MBTL1 (0.39) | DPP4CYP3A4TSHRTDP1MAPT | |
| Hydrochloric Acid SCHEMBL15123967 | 0.76 | CYP3A4 (0.38) | DPP4CYP3A4TSHRTDP1MAPT | |
| Hydrochloric Acid SCHEMBL15123970 | 0.76 | CYP3A4 (0.38) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL13945278 | 0.75 | TSHR (0.39) | DPP4CYP3A4TSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | DPP4 2886/4885PIK3CD 3474/4885CYP3A4 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.